Last updated 2 days ago
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
525 patients around the world
Available in Argentina, United States, Colombia, Brazil, Spain
Bristol-Myers Squibb
12Research sites
525Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following.I) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.Ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein electrophoresis (uPEP) or.Iii) For participants without measurable disease in sPEP or uPEP: serum free light chain levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light chain ratio.Participant has received at least one prior line of anti-myeloma therapy. Note: One line can contain several phases (e.g., induction, [with or without] hematopoietic stem cell transplant, (with or without) consolidation, and/or [with or without] maintenance therapy).Participant must have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an anti-CD38 mAb and received < 2 cycles are still eligible).Participant achieved minimal response or better to at least 1 prior anti-myeloma therapy.Participant must have documented disease progression during or after their last antimyeloma regimen.
- Participant who has had prior treatment with mezigdomide or carfilzomib.Participant has previously received allogeneic stem cell transplant at any time or received autologous stem cell transplant within 12 weeks of initiating study treatment.Other protocol-defined Inclusion/Exclusion criteria apply.
Sites
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Sanatorio 9 de Julio - Tucumán
Recruiting
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
Recruiting
Sanatorio Allende (Nueva Córdoba)
Recruiting
Fundação Antônio Prudente - CAPEC - Centro de Apoio à Pesquisa Clínica
Recruiting
Hospital Mãe de Deus - Porto Alegre
Recruiting
Instituto Americas - COI
Recruiting
Hospital Sao Rafael
Recruiting
Hospital Pablo Tobón Uribe
Recruiting
StudySUCCESSOR-2
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
Multiple myeloma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05552976
